A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of
HLX208 (BRAF V600E Inhibitor) in Advanced Solid Tumor With BRAF V600 Mutation